Answers are grounded in this paper and cite their sources.
Demonstrates antiarthritic effects of a novel compound in rheumatoid arthritis, suggesting new therapeutic avenues.
Rheumatoid arthritis is a systemic autoimmune disorder with a markedly unmet clinical need for highly effective and well-tolerated therapeutic agents with minimal toxicity. Herein, 15 C20-diterpenoid alkaloids, including nine novel compounds, delphyuanines A-I ( 1 – 9 ), were isolated from Delphinium yuanum Chen. Notably, delphyuanine A ( 1 ) represents an exceptionally rare vakognavine-type C20-diterpenoid alkaloid with only 22 congeners of this subclass reported to date. Furthermore, in an LPS-induced macrophage inflammation model, nitric oxide production was substantially inhibited by Compound 1, and its inhibitory effect was markedly stronger than that of the other isolated compounds. Moreover, Compound 1 exhibits potent antiarthritic efficacy in an adjuvant-induced arthritis rat model. Using a probe-affinity labeling assay, the transcription factor FoxO1 was confirmed to be the direct molecular target of Compound 1 . Further molecular mechanistic studies demonstrated that Compound 1 exerts antirheumatoid arthritis activity by directly targeting FoxO1, thereby inhibiting its nuclear translocation, promoting M2 macrophage polarization, and suppressing the NF-κB signaling pathway. Collectively, these findings provide valuable guidance for the rational design of anti-RA drugs and identifies Compound 1 as a promising lead compound for the treatment of autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: